A chemotherapy-free regimen offered durable disease control for certain patients with advanced breast cancer, according to results of the phase 1/phase 2 ASPIRE trial.The regimen — which consists of ...

Researchers pooled data from phase 3 BRUIN CLL-313 and BRUIN CLL-314 clinical trials to assess efficacy and safety of pirtobrutinib in treatment-naive patients with chronic lymphocytic leukemia /small ...

Discussions Around the DeLLphi-305 Trial / Amgen, Antonio Calles, AstraZeneca, cancer, DeLLphi-305, Durvalumab, ESMO, Estela ...

September 10, 2026) - Cabral Gold Inc.  (TSXV: CBR) (OTCQX: CBGZF) ("Cabral" or the "Company") is pleased to announce the ...

Olema Pharmaceuticals gets a Hold rating again as its current valuation reflects both potential and significant execution risks. Click for an OLMA update.

Analysts propose that this positive readout in ES-SCLC could see Imdelltra move into the frontline setting within this indication.

Ku, MD, highlights emerging therapies in the treatment paradigm for patients with gastric and gastroesophageal junction cancers. In a recent interview with Targeted Oncology, Geoffrey Y. Ku, MD, ...

Elevra’s Chief Executive Officer and Managing Director, Mr Lucas Dow, said: “The NAL Expansion PFS confirms a compelling value proposition for Elevra, with a high-return brownfield expansion that ...

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

Australia-based developer Brazilian Rare Earths (BRE) has produced its first rare earth concentrate at its stage one pilot facility in Camacari, located in Brazil's northeastern Bahia state.